Chiesi.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
Earlier this month
One to three months ago
-
Seeking validation for next-gen pMDIs in Europe.Some support1 report
-
Chiesi presented abstracts at the SSIEM congress in Helsinki, Finland.Some support2 reports
-
Gossamer Bio regained full global rights from Chiesi, while facing FDA review issues and authorizing a reverse split for Nasdaq compliance.Some support2 reports
-
Pfizer reported $5.6 million in sales to Chiesi and announced changes to its Chief Financial Officer.Some support2 reports
-
Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.Some support2 reports1 development inside
-
An analyst suggested that a specific stock, involving Chiesi, could be the next major success story after Nvidia.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around Chiesi this week
News at the entities that move Chiesi most-
European Medicines Agency StructuralForbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.Moves Chiesi
-
European Commission StructuralAustralia joins EU research fund and Albanese meets with the European Commission President.Moves Chiesi
-
Pfizer OperationalA building collapse occurred in Brooklyn, following prior structural issues in a Manhattan skyscraper that was formerly Pfizer's headquarters.Moves Chiesi
-
Nvidia Mentioned togetherKhanna sold shares in Nvidia before the CEO scandal broke.Moves Chiesi
-
Singapore Shared contextFlashlight Capital, a Singapore-based activist firm, led a campaign at SECOM.Moves Chiesi
-
UCB Mentioned togetherUCB held a reception in Tucson on November 12, 2026.Moves Chiesi
Connections
The 13 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Gossamer Bio (United States) Operational
Gossamer Bio and Chiesi maintain a strategic partnership involving joint development and financial collaboration.
-
Pfizer Operational
The relationship is characterized by a partnership structure where Chiesi contributes to global product penetration, while Pfizer provides steady market demand for Chiesi's products.
-
European Medicines Agency Structural
Chiesi seeks validation for its products from the European Medicines Agency for market access in Europe.
-
European Commission Structural
The European Commission regulates Chiesi through formal product approvals and oversight.
-
IMPULSE Operational
Chiesi provides support for the Impulse initiative.
-
CRISPR Therapeutics Mentioned together
The entities are co-mentioned as mid-to-mega-cap healthcare stocks within the market context.
-
Pediatric Dermatology Research Alliance Mentioned together
Chiesi presented data at the Pediatric Dermatology Research Alliance conference.
-
Nvidia Mentioned together
An analyst compared the stock potential of Chiesi to Nvidia.
Show all 13 connections
-
Singapore Shared context
Chiesi operates within Singapore by supporting local initiatives like NSG Bio.
-
UCB Mentioned together
The entities are co-mentioned as participants in broader life sciences industry discussions.
-
Helsinki Shared context
Chiesi presented abstracts at a symposium held in Helsinki.
-
Finland Shared context
Chiesi conducted a presentation event within Finland.
-
FDA Shared context
Both entities operate within the regulated pharmaceutical market context.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
2 eventsShow 2 earlier months
July 2026
1 eventJune 2026
4 events- Pfizer reported $5.6 million in sales to Chiesi and announced changes to its Chief Financial Officer.
- Gossamer Bio and Chiesi announced a joint collaboration to develop seralutinib under global collaboration.
- Chiesi gained control of KalVista's headquarters and lab space.
- Hansa Biopharma, Chiesi, and UCB participated in life sciences discussions in Lisbon.